These examples are meaningless as they have no relevance to Clinuvel. PW has already stated data from Scenesse will be used to back an application for Prenumbra. Safety record is unimpeachable. Stroke being a top ten killer globally and huge economic burden on society will see regulators look favourably on the drug should it pass the trials (no reason to expect it won’t). Of course it pays to show prudence when investing but in this case I think Clinuvel is onto a winner. Prenumbra is afamelanotide, the only difference being the use of polymers which will allow the drug to remain in the system longer to provide optimal benefits especially where stroke and myocardial infarction are concerned. Clinuvel was unambiguous in their statement about wanting to treat 70-80% of non-treatable strokes. You don’t have to be Stephen Hawking to work out that it is more than a blockbuster, it is the singular event that will make Clinuvel famous.
CUV Price at posting:
$28.42 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)